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Abstract
Introduction: The G protein-coupled estrogen receptor (GPER) is a novel estrogen receptor that mediates proliferative
effects induced by estrogen but also by tamoxifen. The aim of our study was to analyze the frequency of GPER in a large
collective of primary invasive breast carcinomas, with special emphasis on the subcellular expression and to evaluate the
association with clinicopathological parameters and patient overall survival.
Methods: The tissue microarrays from formalin-fixed, paraffin embedded samples of primary invasive breast carcinomas
(n = 981) were analyzed for GPER expression using immunohistochemistry. Expression data were compared to the
clinicopathological parameters and overall survival. GPER localization was also analyzed in two immortalized breast cancer
cell lines T47D and MCF7 by confocal immunofluorescence microscopy.
Results: A predominantly cytoplasmic GPER expression was found in 189 carcinomas (19.3%), whereas a predominantly
nuclear expression was observed in 529 cases (53.9%). A simultaneous comparable positive expression of both patterns was
found in 32 of 981 cases (3.2%), and negative staining was detected in 295 cases (30%). Confocal microscopy confirmed the
occurrence of cytoplasmic and nuclear GPER expression in T47D and MCF7. Cytoplasmic GPER expression was significantly
associated with non-ductal histologic subtypes, low tumor stage, better histologic differentiation, as well as Luminal A and B
subtypes. In contrast, nuclear GPER expression was significantly associated with poorly differentiated carcinomas and the
triple-negative subtype. In univariate analysis, cytoplasmic GPER expression was associated with better overall survival
(p = 0.012).
Conclusion: Our data suggest that predominantly cytoplasmic and/or nuclear GPER expression are two distinct
immunohistochemical patterns in breast carcinomas and may reflect different biological features, reason why these patterns
should be clearly distinguished in histological evaluations. Prospective studies will be needed to assess whether the
expression status of GPER in breast carcinomas should be routinely observed by clinicians, for instance, before
implementing endocrine breast cancer treatment.
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Introduction
The G protein-coupled estrogen receptor (GPER), formerly also
known as G protein receptor 30 (GPR30), was identified as a novel
estrogen receptor that mediates a rapid, non-genomic response to
estrogens [1]. Interestingly tamoxifen and fulvestrant are also
important known activating GPER ligands [1]. Although tamox-
ifen and fulvestrant are used therapeutically to inhibit the 17beta-
estradiol signaling pathway in breast cancer, it has been shown in
an immortalized human breast cancer cell line (MCF7) that these
drugs lead to an agonistic activation of GPER that results in
stimulated proliferation via EGFR transactivation [2]. Therefore,
GPER has also been experimentally showed to mediate the
proliferative effects of tamoxifen in the endometrium [3].
Supporting these findings, GPER expression has been clinically
correlated with tamoxifen-induced endometrial thickening and
bleeding [4].
Previous studies in breast cancer patients reported an associa-
tion of GPER expression with an increased metastatic potential
and a poorer prognosis [5]. GPER may also play an important
role in developing tamoxifen resistance in breast cancer, because
GPER activation leads to a suppression of the TGF-beta signaling,
which is supposed to be an important mechanism in this process
[6]. However, in breast cancer cells that were negative for the
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classical estrogen receptors, it has also been shown that estrogen or
hydroxytamoxifen were able to induce cell proliferation and
migration via an activation of GPER, which seems to be mainly
mediated by the connective tissue growth factor (CTGF) [7].
This mechanism is of great clinical relevance because it
indicates that tamoxifen may have a cancer-promoting effect
through GPER, which raises the question whether GPER
expression should be assessed routinely in breast cancer patients.
This question is supported by the results of a study that reported
on significantly reduced survival in patients with initially GPER-
positive tumors who were treated with tamoxifen compared to
GPER-negative tumors, which suggests that patients with a high
GPER expression should not be treated with tamoxifen alone [8].
In the literature, GPER has been reported to be expressed in
approximately 60% of all breast carcinomas [1]. However, data
about the expression frequency and subcellular expression pattern
of GPER in breast carcinomas are based on a rather limited
number of immunohistochemical studies [5,8,9]. Whereas only the
cytoplasmic GPER expression was detected in two of these studies
[5,9], breast cancer specimens showing a cytoplasmic and nuclear
staining were described in another study [8].
The aim of our study was to investigate the GPER expression
rate and pattern in a large collective of breast carcinomas, with
special emphasis on the subcellular GPER expression pattern in
correlation to relevant clinicopathological factors and patient
overall survival.
Materials and Methods
Patients
The study was approved by the local ethics committee (ref.
number StV-Nr. 12-2005; Kantonale Ethikkommission Zu¨rich,
Stampfenbachstrasse 121, 8090 Zu¨rich, Switzerland). The local
ethics committee waived the need for written informed consent
from the participants for this retrospective tissue microarray study.
Tissue microarrays from formalin-fixed, paraffin-embedded sam-
ples of primary invasive breast carcinomas were constructed as
previously described [10]. The carcinomas were diagnosed at the
Institute of Surgical Pathology (University Hospital Zurich,
Switzerland) between 1991 and 2005. Tumor tissue samples from
981 patients (female n = 976 and male n= 5) were suitable for
investigation. The histological type was based on the 2003 WHO
classification. Tumor grading was performed according to Bloom
and Richardson [11], as modified by Elston and Ellis [12]. The
hormone receptor expression, Her2 status as well as MIB1 (Ki-67)
proliferation index (cut-point 10%) were previously analyzed
[10,13]. All of the carcinomas were classified according to the so-
called intrinsic subtypes, such as Luminal A and B, HER2 positive
and triple-negative [14].
Immunohistochemistry
Tissue microarray sections were processed using the Ventana
Benchmark automated staining system (Ventana, Tuscon, AZ,
USA). For the antigen retrieval, the slides were incubated with cc1
buffer (cell conditioning solution cc1; tris-based buffer with slightly
alkaline pH 6) for 10 min. Staining was performed with a rabbit
polyclonal anti-GPCR (GPR30, GPER) antibody (Abcam,
ab39742, dilution 1:50). The specificity of this antibody has been
verified in two independent studies [15,16]. We used the same
antibody for another study, which therefore served as a positive
control [17]. Normal breast tissues (n = 52) were included on the
TMAs and served as an internal positive control. Negative controls
by omission of the primary antibody were included. An evaluation
of the immunohistochemical staining was performed by two
authors (AN, AM).
Figure 1. Immunohistochemical expression of GPER in invasive breast carcinoma. A: A predominantly cytoplasmic expression in a
moderate differentiated invasive ductal carcinoma. B: A predominantly cytoplasmic expression in a well differentiated invasive ductal carcinoma with
a perinuclear accentuation. C: Strong nuclear expression in a poorly differentiated invasive ductal breast cancer. D: Epithelium of terminal ductal-
lobular units of normal breast tissue shows strong nuclear expression. The magnification of all images is 2006.
doi:10.1371/journal.pone.0083296.g001
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Immunofluorescence microscopy
The three used immortalized breast carcinoma cell lines
(MCF7, T47D, and MDA-MB231) were cultured using standard
methods in DMEM supplemented by 10% fetal bovine serum and
1% antibiotic/antimycotic substance in an incubator at 37uC in an
atmosphere of 5% CO2 and 95% humidity. MDA-MB231 is a
GPER-negative cell line [18] and was included as a negative
control. The dishes were subcultured when 90% confluence was
Figure 2. Analysis of GPER localization by conventional and confocal immunofluorescence microscopy. Representative images of two
independent experiments each performed in duplicates. A: Immunofluorescence microscopy showing a different expression pattern in MCF7
(predominantly nuclear) and T47D (predominantly cytoplasmic). The GPER-negative MDA-MB231 cell line was used as negative control. B: Confocal
microscopy in T47D and MCF7 using a Leica SP5 microscope (with Leica HyD hybrid detection system). T47D show a strong GPER expression which is
mainly localized in the cytoplasm of the cell. No distinct membranous expression was observed. MCF7 show a less strong GPER expression, which is
clearly detectable inside the nucleus by analysis of the confocal images.
doi:10.1371/journal.pone.0083296.g002
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attained. For the immunofluorescence experiments, subcultured
cells were directly seeded on microscopy coverslips and allowed to
attach for 24 h in the culture dish. The coverslips were then
fixated in 4% paraformaldehyde, permeabilized with PBS 0.2%
triton x-100 and blocked in bovine serum albumin 5%. The same
primary rabbit polyclonal anti-GPCR (GPR30, GPER) antibody
(Abcam, ab39742, dilution 1:100) as for the immunohistochem-
istry was used for these experiments. Incubation with the primary
antibody was done at 4uC overnight. After washing 3-times in PBS
the coverslips were incubated in the secondary anti-rabbit
antibody Alexa Fluor 488 (Invitrogen, dilution 1:1000) for
30 min, washed 3-times in PBS, mounted in DAPI staining and
transferred on microscope slides. The complete experiments were
performed two times independently and each of them in
duplicates. Conventional (Leica DMI6000B) and confocal (Leica
SP5, using the hybrid detection system Leica HyD) immunoflu-
orescence microscopy was performed. 3-dimensional analysis of
the confocal images was done using Imaris software (version 7.6.4,
Bitplane, Zurich, Switzerland).
Statistics
The statistical analysis was performed using the IBM SPSS
version 20 (SPSS Inc., Chicago, IL, USA). The GPER expression
data were dichotomized according to the median in negative and
positive groups. Fisher’s exact test was used to assess the statistical
significance of the associations between the GPER expression and
clinicopathological features. The univariate survival analysis was
performed using Kaplan-Meier method, survival curves were
compared with the log-rank test. Additionally, univariate and
multivariate COX regression analyses were carried out. Only
cases with clinical follow-up data (n = 782) were considered for the
survival analysis. P-values,0.05 were considered as significant.
Results
Expression of GPER in invasive breast carcinomas
The GPER immunohistochemistry revealed two distinct
expression patterns: predominantly nuclear and/or predominantly
cytoplasmic. Therefore, both patterns were evaluated separately
for each sample. Representative images of the staining pattern are
indicated in Figure 1. In total, 981 primary invasive carcinomas
were investigated for GPER expression. Cytoplasmic expression
was found in 189 cases (19.3%), whereas nuclear expression was
observed in 529 cases (53.9%). Simultaneously, the positive
expression of both patterns was found in 32 of 981 cases (3.2%)
and negative staining was detected in 295 cases (30%). The
repartition in either the cytoplasmic or the nuclear GPER
expression pattern was significant for the breast cancer samples
(p,0.0001). Nuclear but no cytoplasmic staining was observed in
the luminal and myoepithelial cells of all the normal breast tissue
samples (n = 52).
Localization of GPER in breast cancer cell lines
The breast carcinoma cell lines T47D and MCF7 showed
different GPER expression patterns in the immunofluorescence
experiments (Figure 2a). We observed a strong GPER expression
in T47D which was mainly localized in the cytoplasm. In contrast,
MCF7 which in comparison expressed GPER less strongly showed
a mainly nuclear localization of GPER. Both localizations were
confirmed by confocal microscopy as shown in Figure 2b.
Association of GPER with clinicopathological factors
The clinicopathological characteristics of the breast carcinomas
are shown in Table 1. Follow-up data were available in 782 of the
cases. The median follow-up period was 47 months (range 0 to 394
months). The adjuvant therapy data were unavailable.
To evaluate an association of GPER expression in breast cancer
with clinicopathological parameters, we performed a statistical
analysis as given in Table 2. We observed that cytoplasmic GPER
expression was significantly associated with histologic subtypes
other than invasive-ductal, low tumor stage (pT1), well and
moderate histologic grade, and Luminal A and B ‘‘intrinsic
subtypes’’.
In contrast, nuclear GPER expression was significantly associ-
ated with a higher histologic grade (poorly differentiated
carcinomas) and triple-negative ‘‘intrinsic subtype’’.
Association of GPER with overall survival
In the univariate survival analysis, positive cytoplasmic GPER
expression was associated with better overall survival (log rank,
p = 0.012), as shown in Figure 3. In a multivariate analysis,
adjusted for other prognostic clinicopathological factors like
patient age, tumor and nodal stage, histologic grade and so-called
intrinsic subtypes (as shown in Table 3), the prognostic significance
Table 1. Clinicopathological parameters of the primary
invasive breast carcinomas (n = 981).
Characteristics n %
Age at diagnosis
,60 years 383 39.0
$60 years 418 42.6
missing 180 18.3
Histologic subtype
ductal 777 79.2
lobular 139 14.2
others 63 6.4
missing 2 0.2
Tumor stage
pT1 393 40.1
pT2–4 585 59.6
missing 3 0.3
Nodal stage
pN0 364 37.1
pN1–3 489 49.8
unknown 128 13.0
Histologic grade
G1 150 15.3
G2 471 48.0
G3 345 35.2
unknown 15 1.5
Subtypes*
Luminal A 216 22.0
Luminal B (HER2 2) 432 44.0
Luminal B (HER2 +) 70 7.1
HER2 51 5.2
Triple negative 112 11.4
unknown 100 10.2
*The carcinomas were classified according to the so-called intrinsic subtypes
[13].
doi:10.1371/journal.pone.0083296.t001
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of cytoplasmic GPER could not be confirmed. Nuclear GPER
expression did not show any correlation with overall survival.
Discussion
Our study provides the immunohistochemical staining results of
GPER in the largest cohort of 981 primary breast carcinomas to
date. We observed GPER expression (predominantly cytoplasmic
and/or nuclear) in 70% of the studied breast carcinomas. GPER
expression was distinguishable between the cytoplasmic (19.3% of
the carcinomas) and nuclear (53.9%) compartment. The majority
of the tumor specimen showed either nuclear or cytoplasmic
staining, whereas only 3.2% of the tumors showed simultaneous
nuclear and cytoplasmic staining. No distinct membranous
staining was detectable neither by immunohistochemistry in the
tissue microarray nor by immunofluorescence in the immortalized
breast cancer cell lines MCF7 and T47D.
The rate of cytoplasmic GPER expression, however, was
markedly lower in our study compared with two previous reports
that observed cytoplasmic expression in approximately 60% of the
breast carcinoma cases [5,8]. Although this may most likely be the
result of a different patient collective and number of cases, it has of
course also to be noted that different antibodies against GPER
were used in each of the two mentioned studies as well as in our
study.
The expression pattern of GPER and its subcellular localization
is still a subject of debate. Because these specimens were placed on
the same tissue microarray, it is not likely that the distribution of
cytoplasmic and nuclear GPER staining that was observed in our
study was simply the result of an artifact. Moreover, the specificity
Table 2. Correlation between the clinicopathological factors and GPER expression.
Clinicopathological characteristics GPER cytoplasmic GPER nuclear
negative positive p negative positive p
Total n=981 792 (80.7%) 189 (19.3%) 452 (46.1%) 529 (53.9%)
Age at diagnosis (n=801) 0.979 0.747
,60 years (n = 383) 314 (82%) 69 (18%) 167 (44%) 216 (56%)
$60 years (n = 418) 343 (82%) 75 (18%) 187 (45%) 231 (55%)
Histologic subtype (n =979) 0.005 0.062
ductal (n = 777) 638 (82%) 139 (18%) 351 (45%) 426 (55%)
lobular (n = 139) 110 (79%) 29 (21%) 63 (45%) 76 (55%)
others (n = 63) 42 (67%) 21 (33%) 38 (60%) 25 (40%)
Tumor stage (n =978) 0.020 0.711
pT1 (n = 393) 303 (77%) 90 (23%) 178 (45%) 215 (55%)
pT2–4 (n = 585) 486 (83%) 99 (17%) 272 (46%) 313 (54%)
Nodal stage (n=853) 0.801 0.541
pN0 (n = 364) 290 (80%) 74 (20%) 165 (45%) 199 (55%)
pN1–3 (n = 489) 393 (80%) 96 (20%) 232 (47%) 257 (53%)
Histologic grade (n=966) ,0.0001 0.005
G1 (n = 150) 101 (67%) 49 (33%) 73 (49%) 77 (51%)
G2 (n = 471) 366 (78%) 105 (22%) 240 (51%) 231 (49%)
G3 (n = 345) 314 (91%) 31 (9%) 133 (39%) 212 (61%)
Subtypes* (n =881) ,0.0001 ,0.0001
Luminal A (n = 216) 160 (74%) 56 (26%) 107 (50%) 109 (50%)
Luminal B (HER22) (n = 432) 330 (76%) 102 (24%) 214 (50%) 218 (50%)
Luminal B (HER2+) (n = 70) 58 (83%) 12 (17%) 33 (47%) 37 (53%)
HER2 (n = 51) 51 (100%) 0 22 (43%) 29 (57%)
Triple negative (n = 112) 109 (97%) 3 (3%) 35 (31%) 77 (69%)
ER (n =933) ,0.0001 0.003
negative (n = 167) 164 (98%) 3 (2%) 59 (35%) 108 (65%)
positive (n = 766) 589 (77%) 177 (23%) 369 (48%) 397 (52%)
PR (n =720) ,0.0001 0.007
negative (n = 247) 221 (89%) 26 (11%) 99 (40%) 148 (60%)
positive (n = 473) 368 (78%) 105 (22%) 240 (51%) 233 (49%)
HER2 (n =935) 0.006 0.965
negative (n = 812) 641 (79%) 171 (21%) 378 (47%) 434 (53%)
positive (n = 123) 110 (89%) 13 (11%) 57 (46%) 66 (54%)
*Intrinsic subtypes [13].
doi:10.1371/journal.pone.0083296.t002
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of the same antibody used in our study has been verified in an
independent study using shRNA for GPER (negative control) as
well as the specific inducer G1 (positive control) [15] and it has
been shown in a second study using the western blot technique
that this antibody does not bind to ER-alpha [16]. Our
immunofluorescence experiments confirm the specificity of the
antibody and different GPER localization depending on the cell
line (predominantly cytoplasmic localization in T47D and mainly
nuclear localization in MCF7). Confocal microscopy evidenced
the occurrence of both, cytoplasmic and nuclear localizations in
these cell lines.
The distinct histopathological occurrence of cytoplasmic and
nuclear GPER expression observed in our study may most likely
be explained by studies that have investigated the dynamical
changes of the subcellular localization of GPER [19,20]. It has
been shown by cellular surface labeling that a retrograde transport
of GPER from the plasma membrane towards the nucleus occurs
with a consecutive accumulation of GPER in the perinuclear space
followed by a later dispersion in the cytoplasm [20]. Additionally,
in another recent study it has been shown that estradiol can
stimulate nuclear translocation of GPER in breast cancer-
associated fibroblasts, indicating that GPER also mediates a
nuclear signaling pathway [21,22]. Although the biological
meaning of subcellular GPER trafficking has not been definitively
clarified, it may be the result of a functional receptor modulation
[20], which is of major importance because it could possibly
implicate a different biological response to GPER signaling in
different breast carcinomas. The observed different staining
pattern may therefore be the reflection of a dynamic time-
dependent intracellular GPER trafficking process, which never-
theless may be differently modulated according to the biological
characteristics of different breast carcinoma subtypes.
Our results showed that cytoplasmic GPER expression was
associated with low tumor stage and well- to moderately
differentiated carcinomas. Moreover, cytoplasmic GPER expres-
sion was significantly associated with hormone receptor-positive
breast carcinoma subtypes Luminal A and B. These results are in
line with the results of Ignatov et al., which showed a tendency to
associate cytoplasmic GPER positivity with ER and PR positive
breast carcinomas [8]. Filardo et al. described a significant
association of cytoplasmic GPER positivity to ER positivity but did
not observe an association with PR expression [5]. Most likely
because of the larger number of analyzed invasive breast
carcinoma samples in our study compared with these studies, we
were clearly able to observe a significant correlation between
cytoplasmic GPER positivity and ER- and PR-positive breast
carcinoma samples.
In contrast to the cytoplasmic GPER expression, we observed
that nuclear GPER expression was associated with poorly
differentiated carcinomas and a triple-negative intrinsic subtype.
This opposite association of cytoplasmic and nuclear-localized
GPER with clinicopathological parameters might be the reflection
Figure 3. Kaplan-Meier analysis: Better overall survival in patients with positive cytoplasmic GPER expression compared to
negative cytoplasmic GPER expression (log rank, p=0.012).
doi:10.1371/journal.pone.0083296.g003
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of a different biological significance of the two different subcellular
GPER localizations [20].
Despite recent data [5,8,9,23], the clinical relevance of GPER
in breast cancer remains relatively poorly investigated. GPER
expression in breast cancer is of clinical relevance because it has
been shown that GPER may trigger a proliferative response to
estrogen in cases of ER-alpha and ER-beta negative but GPER-
positive breast cancers [7]. GPER may also be implicated in the
processes of decreased sensitivity or resistance to tamoxifen in ER-
positive and GPER-positive breast cancer because tamoxifen is
known to cause a GPER-mediated proliferative effect in breast
cancer cells [6,7]. Furthermore, GPER is most likely involved in
the endometrial proliferation that is frequently observed in
tamoxifen treatment [3,4].
In their study of 323 patients and a confirmation cohort of 103
patients, Ignatov et al. found an association between increased
GPER expression and a shorter RFS in patients undergoing
tamoxifen therapy. Conversely, in patients who were not subjected
to a tamoxifen therapy, GPER was associated with a longer RFS.
In addition, the authors were able to demonstrate in 33 paired
biopsies (before and after adjuvant therapy) that GPER expression
significantly increased only under tamoxifen treatment [8].
One limitation of our study was the fact that the clinical data on
systemic therapy were not available. Consequently, we were
unable to verify the relationship between GPER expression and
resistance to anti-hormonal drugs in our collective. Our data
provide a purely descriptive approach to the relationship between
GPER expression status and different tumor characteristics.
Further studies are warranted to provide more mechanistic data
and information about possible GPER protein modifications
which were not subject of this study. Even if the subcellular
localizations of the detected GPER protein were confirmed by
confocal microscopy, it is not excluded that other forms of GPER
were not detectable and it is not proven that all the detected forms
were reflecting a fully functional protein. Nevertheless, our data is
clearly indicating a differential subcellular GPER expression
between different invasive breast carcinoma tissue and cell lines,
which is associated with different clinicopathological characteris-
tics and should be taken into consideration in further studies.
Conclusion
In conclusion, our data suggest that cytoplasmic and nuclear
GPER expression are two relatively distinct immunohistochemical
patterns in breast carcinomas and may reflect different biological
features; therefore, these patterns should be clearly distinguished in
histological evaluations. Our findings provided a systematic
analysis of the GPER expression pattern in a large number of
breast carcinomas, which indicated that cytoplasmic GPER
expression in breast carcinomas is generally associated with a
better clinical outcome, whereas a nuclear GPER expression is
associated with less favorable tumor properties. The intracellular
trafficking of GPER has been shown in vitro [19,20] and may
reflect distinct biological behavior of the tumors, which must be
further investigated in future studies. Prospective studies will be
needed to assess whether the expression status of GPER in breast
carcinomas should be routinely observed by clinicians, for
instance, before implementing breast cancer treatment with
tamoxifen. Nevertheless, it appears to be of importance to
distinguish between distinct subcellular localizations when assess-
ing the GPER expression pattern immunohistochemically in
breast carcinomas, which will also be relevant for upcoming
studies in this field.
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